Document is current

Any future updates will be listed below

Correction: Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis

Crossref DOI link: https://doi.org/10.1007/s12325-026-03532-4

Published Online: 2026-03-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark